Bioavailability of Orally Administered rhGM-CSF: A Single-Dose, Randomized, Open-Label, Two-Period Crossover Trial

Wenping Zhang, Zhengbing Lv, Zuoming Nie et al. · 2009

Read Bioavailability of Orally Administered rhGM-CSF: A Single-Dose, Randomized, Open-Label, Two-Period Crossover Trial by Wenping Zhang, Zhengbing Lv, Zuoming Nie et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0005353.txt.

Description

A growth factor called rhGM-CSF boosts white blood cell production and is normally given by injection. No clinical report of giving it by mouth existed. Zhang and colleagues ran a single-dose crossover trial of the oral form in healthy volunteers in PLOS ONE in 2009.

Volunteers received the protein by mouth in a randomized, open-label design with two periods. The trial demonstrated the bioavailability of the oral dose, as the abstract states. A pill form would spare patients repeated injections, if later trials confirm the early result. Most proteins are digested in the gut, so a pill form of a protein drug is a surprise worth a close look. And the trial design used here gives a clean first read on it.

Catalog record

CREATORWenping Zhang, Zhengbing Lv, Zuoming Nie et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005353

Browse the full library · About the Tower of Babel